Fabiani C, et al. - In patients with refractory sight-threatening retinal vasculitis (RV), researchers assessed tumor necrosis factor (TNF)-α blockers adalimumab (ADA) and infliximab (IFX) for their effectiveness during a 12-month follow-up period. In addition, they evaluated any impact of concomitant conventional disease-modifying anti-rheumatic drugs (cDMARDs) and different lines of biologic therapy, any difference in effectiveness between ADA and IFX, consequences of biotherapies on the best-corrected visual acuity (BCVA), corticosteroid-sparing effect, and ocular complications during anti-TNF-α treatment. Findings suggest anti-TNF-α monoclonal antibodies have excellent results in these patients. They observed no differences in terms of RV resolution between patients taking monotherapy vs those co-administered cDMARDs at 3-month and 12-month follow-up, biologic-naïve patients vs those already exposed to other biologics at 3-month and 12-month visits, and patients treated with ADA vs those treated with IFX. Researchers noted a statistically significant corticosteroid-sparing effect, while there appeared no significant change in BCVA values.